Liteng Lin

1.6k citations

40 papers · 1.3k · 1 hit paper · h-index 20

Impact in

Hepatology top 2%
- Hepatocellular Carcinoma Treatment and Prognosis
Biomaterials top 5%
- Nanoparticle-Based Drug Delivery

Papers in

Hepatology 16
- Hepatocellular Carcinoma Treatment and Prognosis 11
- Liver physiology and pathology 5
Immunology 12
- Immunotherapy and Immune Responses 5

Co-authors: Kangshun Zhu (29 shared papers)Xintao Shuai (13 shared papers)Mingyue Cai (27 shared papers)Wensou Huang (26 shared papers)Jingjun Huang (20 shared papers)Yongjian Guo (21 shared papers)Yong Wang (9 shared papers)Licong Liang (15 shared papers)
Journals: Biomedicine & Pharmacotherapy (3 papers)Biomaterials Science (3 papers)Journal of Controlled Release (2 papers)Nanomedicine Nanotechnology Biology and Medicine (2 papers)Bioactive Materials (1 paper)
Partner nations: China United States Hong Kong

In The Last Decade

Liteng Lin

40 papers receiving 1.3k citations

Liteng Lin's Hit Papers

align trajectories log scale

Transarterial Chemoembolization Combined With Lenvatinib Plus PD-1 Inhibitor for Advanced Hepatocellular Carcinoma: A Retrospective Cohort Study 2022 · 136 citations

What are hit papers?

Paper score: A paper's citations measured against the top-1% bar of its own field and year: the square root of citations ÷ bar, so 1 means right at the bar and 2 means four times its citations. The bar blends the citation counts that enter the top 1% of the paper's subfields in its year (weighted 89.5%), of those subfields over all years (0.5%) and of its year across all fields (10%); a subfield and year with fewer than 400 papers takes its year's bar. Papers from 2026 are not scored yet: in an unfinished year, when a paper appeared matters more than how it is cited.

Hit paper: A paper cited at least 1.5× the top-1% bar of its field and year: a paper score of at least √1.5.

2022 Frontiers in Immunology

Peers

Countries citing papers authored by Liteng Lin

Since Specialization

Citations

This map shows the geographic impact of Liteng Lin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Liteng Lin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Liteng Lin more than expected).

Fields of papers citing papers by Liteng Lin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Liteng Lin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Liteng Lin. The network helps show where Liteng Lin may publish in the future.

Co-authors

The 25 scholars most cited alongside Liteng Lin, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Liteng Lin Line = papers co-authored together Liteng Lin links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 40 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Dual pH-sensitive nanodrug blocks PD-1 immune checkpoint and uses T cells to deliver NF-κB inhibitor for antitumor immunotherapy Science Advances ·Zecong Xiao, Zhenwei Su, Shisong Han, Jinsheng Huang, Liteng Lin, Xintao Shuai	2020	137
2	Transarterial Chemoembolization Combined With Lenvatinib Plus PD-1 Inhibitor for Advanced Hepatocellular Carcinoma: A Retrospective Cohort Study Frontiers in Immunology ·Mingyue Cai, Wensou Huang, Jingjun Huang, Wenbo Shi, Yongjian Guo, Licong Liang, Jingwen Zhou, Liteng Lin, Bihui Cao, Ye Chen, Juan Zhou, Kangshun Zhu Hit paper breakdown →	2022	136
3	Aortic plaque-targeted andrographolide delivery with oxidation-sensitive micelle effectively treats atherosclerosis via simultaneous ROS capture and anti-inflammation Nanomedicine Nanotechnology Biology and Medicine ·Teng Wu, Xiaoyan Chen, Yong Wang, Hong Ping Xiao, Yuan Peng, Liteng Lin, Wenhao Xia, Ming Long, Jun Yu Tao, Xintao Shuai	2018	104
4	Nanodrug with ROS and pH Dual‐Sensitivity Ameliorates Liver Fibrosis via Multicellular Regulation Advanced Science ·Liteng Lin, (unknown), Rui Li, Jingjun Huang, Mingyue Cai, Tian Lan, Wensou Huang, Yongjian Guo, Zhimei Zhou, Yongcheng An, Zhiwei Chen, Licong Liang, Yong Wang, Xintao Shuai, Kangshun Zhu	2020	86
5	Development of mesothelin-specific CAR NK-92 cells for the treatment of gastric cancer International Journal of Biological Sciences ·Bihui Cao, Manting Liu, Jingjun Huang, Jingwen Zhou, Junping Li, Hui Lian, Wensou Huang, Yongjian Guo, Shuo Yang, Liteng Lin, Mingyue Cai, Cheng Zhi, Jingqiang Wu, Licong Liang, Yuling Hu, Hong‐Ming Hu, Jinping He, Baoxia Liang, Qi Zhao, Kangshun Zhu	2021	85
6	Co-Delivery of Doxorubicin and Anti-BCL-2 siRNA by pH-Responsive Polymeric Vector to Overcome Drug Resistance in In Vitro and In Vivo HepG2 Hepatoma Model Biomacromolecules ·Weitong Sun, Xiaoyan Chen, Chao Lian Xie, Yong Wang, Liteng Lin, Kangshun Zhu, Xintao Shuai	2018	81
7	Nanodrug enhances post-ablation immunotherapy of hepatocellular carcinoma via promoting dendritic cell maturation and antigen presentation Bioactive Materials ·Zecong Xiao, Tan Li, Xinyao Zheng, Liteng Lin, Xiaobin Wang, Bo Li, Jingjun Huang, Yong Wang, Xintao Shuai, Kangshun Zhu	2022	56
8	Andrographolide Ameliorates Liver Fibrosis in Mice: Involvement of TLR4/NF‐κB and TGF‐β1/Smad2 Signaling Pathways Oxidative Medicine and Cellular Longevity ·Liteng Lin, Rui Li, Mingyue Cai, Jingjun Huang, Wensou Huang, Yongjian Guo, Liuhong Yang, Guizhi Yang, Tian Lan, Kangshun Zhu	2018	52
9	Sublethal heat stress-induced O-GlcNAcylation coordinates the Warburg effect to promote hepatocellular carcinoma recurrence and metastasis after thermal ablation Cancer Letters ·Ye Chen, Jiaxin Bei, Mingyu Liu, Jingjun Huang, Lulu Xie, Wensou Huang, Mingyue Cai, Yongjian Guo, Liteng Lin, Kangshun Zhu	2021	50
10	Codelivery of sorafenib and GPC3 siRNA with PEI-modified liposomes for hepatoma therapy Biomaterials Science ·Weitong Sun, (unknown), Mingyue Cai, Liteng Lin, Xiaoyan Chen, Zhong Cao, Kangshun Zhu, Xintao Shuai	2017	50
11	LncRNA DLEU2 aggravates the progression of hepatocellular carcinoma through binding to EZH2 Biomedicine & Pharmacotherapy ·Yongjian Guo, Mingjun Bai, Liteng Lin, Jingjun Huang, Yongcheng An, Licong Liang, Yaohong Liu, Wensou Huang	2019	42
12	Regorafenib Combined with PD-1 Blockade Immunotherapy versus Regorafenib as Second-Line Treatment for Advanced Hepatocellular Carcinoma: A Multicenter Retrospective Study Dove Medical Press (Taylor and Francis Group) ·Jingjun Huang, Yongjian Guo, Wensou Huang, Xiaotao Hong, Yi Quan, Liteng Lin, Jingwen Zhou, Licong Liang, Yaqin Zhang, Juan Zhou, Mingyue Cai, Kangshun Zhu	2022	37
13	A reduction and pH dual-sensitive nanodrug for targeted theranostics in hepatocellular carcinoma Biomaterials Science ·Mingyue Cai, Bo Li, Liteng Lin, Jingjun Huang, Yongcheng An, Wensou Huang, Zhimei Zhou, Yong Wang, Xintao Shuai, Kangshun Zhu	2020	36
14	Nanodrug removes physical barrier to promote T-cell infiltration for enhanced cancer immunotherapy Journal of Controlled Release ·Zecong Xiao, Yitong Tan, Yujun Cai, Jinsheng Huang, Xiaobin Wang, Bo Li, Liteng Lin, Yong Wang, Xintao Shuai, Kangshun Zhu	2023	36
15	MRI-visible and pH-sensitive micelles loaded with doxorubicin for hepatoma treatment Biomaterials Science ·Bo Li, Mingyue Cai, Liteng Lin, Weitong Sun, Zhimei Zhou, Shiyin Wang, Yong Wang, Kangshun Zhu, Xintao Shuai	2019	33
16	Drug-Eluting Bead Transarterial Chemoembolization Combined with FOLFOX-Based Hepatic Arterial Infusion Chemotherapy for Large or Huge Hepatocellular Carcinoma Journal of Hepatocellular Carcinoma ·Jingjun Huang, Wensou Huang, Meixiao Zhan, Yongjian Guo, Licong Liang, Mingyue Cai, Liteng Lin, He Mingji, Hui Lian, Ligong Lu, Kangshun Zhu	2021	30
17	Amelioration of cirrhotic portal hypertension by targeted cyclooxygenase-1 siRNA delivery to liver sinusoidal endothelium with polyethylenimine grafted hyaluronic acid Nanomedicine Nanotechnology Biology and Medicine ·Liteng Lin, Mingyue Cai, Shaohui Deng, Wensou Huang, Jingjun Huang, Xinghua Huang, Mingsheng Huang, Yong Wang, Xintao Shuai, Kangshun Zhu	2017	26
18	Intratumoral Lactate Depletion Based on Injectable Nanoparticles−Hydrogel Composite System Synergizes with Immunotherapy against Postablative Hepatocellular Carcinoma Recurrence Advanced Healthcare Materials ·Ye Chen, Jiaxin Bei, Meijuan Chen, Weiguo Cai, Zhimei Zhou, Mingyue Cai, Wensou Huang, Liteng Lin, Yongjian Guo, Mingyu Liu, Xinkun Huang, Zecong Xiao, Zhili Xu, Kangshun Zhu	2023	24
19	Inhibition of CEMIP potentiates the effect of sorafenib on metastatic hepatocellular carcinoma by reducing the stiffness of lung metastases Cell Death and Disease ·Mingyu Liu, Lulu Xie, Yuying Zhang, Jianning Chen, Xiang Zhang, Ye Chen, Wensou Huang, Mingyue Cai, Licong Liang, Miaoling Lai, Jingjun Huang, Yongjian Guo, Liteng Lin, Kangshun Zhu	2023	21
20	T cell-mediated targeted delivery of tadalafil regulates immunosuppression and polyamine metabolism to overcome immune checkpoint blockade resistance in hepatocellular carcinoma Journal for ImmunoTherapy of Cancer ·Xiaobin Wang, Qiaoyun Zhang, Jingwen Zhou, Zecong Xiao, Jianxin Liu, Shaohui Deng, Xiaoyang Hong, Wensou Huang, Mingyue Cai, Yongjian Guo, Jingjun Huang, Yong Wang, Liteng Lin, Kangshun Zhu	2023	21

About Liteng Lin

Liteng Lin is a scholar working on Hepatology, Immunology, Cancer Research, Oncology and Biomaterials, having authored 40 papers that have together received 1.3k indexed citations. Recurring topics across this work include Hepatocellular Carcinoma Treatment and Prognosis (11 papers), Nanoplatforms for cancer theranostics (8 papers), Cancer Immunotherapy and Biomarkers (5 papers), Nanoparticle-Based Drug Delivery (5 papers), Immunotherapy and Immune Responses (5 papers), Liver physiology and pathology (5 papers), RNA Interference and Gene Delivery (4 papers) and Cancer Mechanisms and Therapy (3 papers). The work is most often cited by research in Hepatology (325 citations), Biomaterials (224 citations), Immunology (274 citations), Cancer Research (140 citations) and Oncology (213 citations). Liteng Lin has collaborated with scholars based in China, United States and Hong Kong. Frequent co-authors include Kangshun Zhu, Xintao Shuai, Mingyue Cai, Wensou Huang, Jingjun Huang, Yongjian Guo, Yong Wang, Licong Liang, Zecong Xiao and Xiaoyan Chen. Their work appears in journals such as Biomedicine & Pharmacotherapy, Biomaterials Science, Journal of Controlled Release, Nanomedicine Nanotechnology Biology and Medicine and Bioactive Materials.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Liteng Lin

Impact in

Papers in i

In The Last Decade

Liteng Lin

Liteng Lin's Hit Papers

Peers

Countries citing papers authored by Liteng Lin

Fields of papers citing papers by Liteng Lin

All Works

About Liteng Lin

Explore authors with similar magnitude of impact

Papers in